Skip to main content

Table 4 Drug specificity of the top 500 genes identified using ProGENI and Pearson correlation scheme using the LCL dataset

From: Knowledge-guided gene prioritization reveals new insights into the mechanisms of chemoresistance

Treatment Rank by ProGENI (p value) Rank by PCC (p value)
6MP 3 (0.13) 1 (0.04)
6TG 23 (0.96) 5 (0.21)
Arac 9 (0.38) 4 (017)
Arsenic 12 (0.5) 12 (0.5)
Carboplatin 5 (0.21) 2 (0.08)
Cddp 8 (0.33) 3 (0.13)
Cladribine 2 (0.08) 3 (0.13)
Docetaxel 1 (0.04) 1 (0.04)
Doxorubicin 2 (0.08) 2 (0.08)
Epirubicin 2 (0.08) 2 (0.08)
Everolimus 12 (0.5) 2 (0.08)
Fludarabine 11 (0.46) 8 (0.33)
Gemcitabine 2 (0.08) 1 (0.04)
Hypoxia 2 (0.08) 1 (0.04)
Metformin 3 (013) 7 (0.29)
MPA 1 (0.04) 1 (0.04)
MTX 13 (0.54) 18 (0.75)
NAPQI 11 (0.46) 1 (0.04)
Oxaliplatin 1 (0.04) 1 (0.04)
Paclitaxel 1 (0.04) 1 (0.04)
Radiation 24 (1) 24 (1)
Rapamycin 2 (0.08) 2 (0.08)
TCN 11 (0.46) 23 (0.96)
TMZ 15 (0.63) 16 (0.67)
  1. A high rank (small entry) shows that the average size of intersection between genes identified using the prioritization method on the two sets of cell lines for the same drug is larger than the intersection when the drug is compared with other drugs. The geometric means of all ranks for prioritization using ProGENI and Pearson correlation are 4.5 and 3.1, respectively